BriaCell is consolidating shares in compliance with Nasdaq listing requirements

From GlobeNewswire: 2025-01-03 17:05:00

BriaCell Therapeutics Corp. has announced a consolidation of its common shares to comply with Nasdaq listing requirements. The consolidation will be effective on January 24, 2025, with post-consolidation shares trading on the TSX and Nasdaq on January 29, 2025. Shareholders will receive one post-consolidation share for every fifteen pre-consolidation shares. No fractional shares will be issued. Instructions for exchanging shares will be provided to registered shareholders. The company’s post-consolidation shares will continue to trade under the symbols “BCT” on the TSX and “BCTX” on the Nasdaq.

For more information, visit BriaCell’s website. The company cautions that forward-looking statements in this press release are subject to risks and uncertainties. Shareholders should review the company’s filings with securities regulatory authorities for a full understanding of these risks. BriaCell Therapeutics Corp. undertakes no obligation to update forward-looking information. Contact William V. Williams, MD, President & CEO, at 1-888-485-6340, or email [email protected] for company inquiries. For media and investor relations, contact Jules Abraham at CORE IR or email [email protected].



Read more at GlobeNewswire: BriaCell Announces Proposed Effective Date of Share